Company profile for Curatis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Curatis, a specialty pharmaceutical company headquartered in Switzerland, specializes in acquiring, licensing, distributing, and promoting medications for the treatment and prevention of orphan and specialty diseases within Switzerland. These medicines are developed and introduced to the market by third-party pharmaceutical firms. With exclusive distribution rights for over 30 different drugs in Switzerland, many of which are ...
Curatis, a specialty pharmaceutical company headquartered in Switzerland, specializes in acquiring, licensing, distributing, and promoting medications for the treatment and prevention of orphan and specialty diseases within Switzerland. These medicines are developed and introduced to the market by third-party pharmaceutical firms. With exclusive distribution rights for over 30 different drugs in Switzerland, many of which are targeted towards orphan and specialty diseases, Curatis solidifies its prominent position within the Swiss orphan drug market.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Weierweg 7 CH-4410 Liestal
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250917939293/en/Curatis-FDA-Minutes-Confirm-Positive-Outcome-of-Meeting-on-9.-September-2025-Corticorelin-on-Track-for-Phase-3

BUSINESSWIRE
18 Sep 2025

https://www.pharmiweb.com/press-release/2025-09-18/fda-minutes-confirm-positive-outcome-of-meeting-on-9-september-2025-corticorelin-on-track-for-pha

PHARMAWEB
18 Sep 2025

https://www.businesswire.com/news/home/20250914049177/en/Curatis-Double-Digit-Growth-in-Core-Business-and-Development-Milestone-Achieved-for-C-PTBE-01

BUSINESSWIRE
15 Sep 2025

https://www.pharmiweb.com/press-release/2025-09-05/curatis-expands-distribution-business-with-phoenix-labs-with-up-to-chf-5m-additional-annual-revenues

PHARMAWEB
05 Sep 2025

https://www.pharmiweb.com/press-release/2025-07-31/fda-confirms-type-b-meeting-on-corticorelin-pivotal-phase-3-study

PHARMAWEB
31 Jul 2025

https://www.businesswire.com/news/home/20250522906458/en/Curatis-discloses-Corticorelin-as-active-substance-of-C-PTBE-01

BUSINESSWIRE
23 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty